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The identification of proteins involved in brain ischemia might allow the discovery of 
putative biomarkers or therapeutic targets for ischemic stroke. Our aim is to study the 
distribution of proteins within mouse brain after an ischemic insult using MALDI 
Imaging-Mass-Spectrometry and to identify relevant proteins involved in brain 
damage. We occluded the middle cerebral artery of C57BL/6J mice. Brain slices were 
analyzed by MALDI-TOF and infarct (IC) and contralateral (CL) regions were compared 
using ClinProTools. The ion distribution maps of relevant m/z values were obtained by 
FlexImagin3.0. Protein identification was conducted through a bottom-up approach 
consisting on complementary sample fractionation methods. Some identifications 
were confirmed by immunohistochemistry and western blot. We identified 102 m/z 
values with different abundances between IC and CL (p<0.05), from which 21 m/z 
peaks were selected as more relevant. Thirteen of them were found increased in the 
infarct region and 4 m/z values showed AUC>90% between IC and CL. Identification 
analyses confirmed altered expressions of ATP5i, COX6C and UMP-CMP kinase in IC 
compared to CL.  
Significance: Using MALDI-IMS we identified for the first time new proteins that might 
be involved in brain ischemia representing potential diagnostic biomarkers or target 


















Ischemic stroke is one of the most important neurological disorders and cause of 
disability worldwide[1]. Brain ischemia is originated by the impairment of blood supply 
into the brain parenchyma due to an arterial occlusion. This process encompasses a 
complex cascade of events that affects both cellular and extracellular matrix 
components including the inflammatory response, the immune cells extravasation, the 
development of edema or the blood-brain-barrier disruption[2]. Finally, it leads to cell 
death and tissue injury which is translated into a loss of neurological functions [3]. The 
identification of key molecules involved in brain injury and repair would help to design 
future treatments for neuroprotection and neurorecovery. 
There are several experimental models of ischemic stroke developed in different 
species, especially rodents. The murine model which consists of the transient occlusion 
of the distal middle cerebral artery exhibits a reproducible cerebral infarct with a 
controlled reperfusion, low mortality rates and measurable neurological impairment 
during the acute phase[4,5]. This model is extremely useful for the study of cerebral 
ischemia pathophysiology and has been extensively used in the discovery of new 
molecules involved in brain injury [6–9]. 
MALDI imaging mass spectrometry (MALDI-IMS) is a powerful technique that allows to 
obtain the profiling of a broad range of molecules [10] such as metabolites[11–16], 
lipids[17–23], proteins[24–26] or drugs[27–31] directly on tissue[32]. In addition, it 
permits to analyze their spatial distribution and their local abundance simultaneously. 
This innovative technique has been proven to be useful for the molecular diagnostic in 
the context of inflammatory diseases[33–35], traumatic injuries[36,37], vascular 
diseases[17,38], neurodegenerative disorders[39] and specially in different types of 
tumors[40,41]. MALDI-IMS has been also employed for the study and visualization of 
lipid distribution in the brain after focal ischemia[42–44]. However, as far as we know 
a complete MALDI IMS profiling of proteins in the context of cerebral ischemia has not 
been yet conducted. The identification of new proteins involved in brain ischemia 














ischemic stroke and new potential therapeutic targets. This deeper knowledge would 
permit the study of pathways related with this sever disorder and its progression. 
In our study we aim to visualize changes in the brain protein profile in a mouse model 
of brain ischemia and to identify new putative biomarkers or therapeutic targets by 
means of MALDI IMS. 
METHODS 
Animals 
Adult male C57BL/6Ncrl mice (body weight from 25 to 30 g) were used for the study. 
Animals were bred in-house in a temperature-/humidity- controlled room and 
maintained on a 12-hour light/ 12-hour dark cycle. The Ethics Committee of Animal 
Experimentation of Vall d’Hebron Research Institute approved the study protocol (No. 
28/15), and all experiments were conducted in accordance with the Spanish legislation 
and the Directives of the European Union. The ARRIVE guidelines were considered 
when designing and reporting the results of the study. A total of 17 mice were 
included. 
Transient middle cerebral artery occlusion (tMCAO) 
The surgery was conducted as previously reported [5]. Briefly, mice were anesthetized 
with isofluorane (4% for induction, 2% for maintenance in air, 79% N2 : 21% O2; Abbot 
Laboratories, Madrid, Spain). Buprenorphin (0.05-0.1 mg/kg) was administered 
subcutaneously as analgesic for post-surgical pain. The distal part of the middle 
cerebral artery (MCA) was exposed after performing a small craniotomy in the left 
temporal bone, leaving the dura intact. The MCA was directly compressed for 60 min 
using a micromanipulator holding a 30G blunted needle decreasing the cerebral blood 
flow to <25% of the baseline values. After the arterial occlusion, the needle was 
removed and the cerebral blood flow (CBF) recovered at least the 75% of the baseline. 
During the entire procedure the body temperature was maintained at 36.5-37ºC using 
a heating blanket and controlled by a rectal probe and the CBF was recorded by laser 
Doppler flowmetry (Moor Instruments, Devon, UK).  After 24 hours animals were 














MALDI-IMS profiling and other MS analyses for protein identification were perfused 
with cold saline, while those used for immunohistochemistry approaches were 
perfused with 4% cold paraformaldehyde (PFA). 
MALDI IMS 
Brain tissue processing, MALDI mass spectrometry and image analysis 
Brains (n=4) were isolated and immediately snap frozen in isopentane (Sigma, USA) at -
40oC during 30 sec and stored at -80oC. Ten µm-thick coronal brain sections (+0.74 to 
+0.98 from bregma) were obtained using a cryostat (Microm HM 505E, CBIS, USA) and 
mounted onto superconductive glass slides covered with ITO coating (Bruker Daltonics, 
Germany). Tissue preparations were dried with vacuum pump (Millipore, USA) at 600 
mmHg for 15 minutes, washed for two minutes in 70% Ethanol and once in 96% 
Ethanol and then stored in a dessicator under vacuum. In order to be analyzed by 
MALDI TOF MS, samples were covered with sinapinic acid (10mg/mL in 60% 
acetonitrile and 0.2% trifluoroacetic acid (TFA)) as MALDI matrix sprayed using 
ImagePrep device (Bruker Daltonics). The device parameters were optimized for the 
brain sections, with a final set-up of 20 cycles combining 2,5s of spray, 5s of incubation 
and 20s of dry time. Finally the slides were mounted into MTP slide adapter (Bruker 
Daltonics) and transferred to the MALDI-TOF mass spectrometer. Four biologically 
independent samples were analyzed by MS.  IMS spectra were acquired in linear 
positive ion mode in an UltrafleXtreme MALDI-TOF/TOF mass spectrometer (Bruker 
Daltonics). MS data were averaged from 300 consecutive laser shots with a frequency 
of 2,000 shot/s. The raster spatial resolution was 100 µm.  
After the MS analysis, hematoxylin & eosin (H&E) staining (Sigma) was performed in 
each brain section and they were used as reference for colocalization to select the 
regions of interest (ROI).  
Data quantification and statistical MALDI-IMS data analysis 
After MALDI analysis, we used FlexImaging 3.0 (Bruker Daltonics, Germany) software 
to obtain ion density maps and to define the ROIs on each brain section. Two ROIs 














the infarct core (IC) at the cerebral cortex and another ROI on the contralateral healthy 
(CL) area. In each brain section a dataset file was obtained with the spectra of each 
pixel contained in the ROIs. Then, all dataset files were combined in a single XML to be 
statistically analyzed with ClinProTools V3.0 software (Bruker Daltonics, Germany). The 
analysis of the mass spectra was focused on the mass range 2,000-24,000 m/z. The 
following settings were used for recalibration: a top hat baseline correction of 10% of 
minimal baseline width, a maximum peak shift of 2,000 ppm for peak alignment and 
20% match to the calibrant peaks. Not recalibratable spectra were excluded from the 
statistical analysis. Signal to noise ratio for data acquisition was set to 5. An average 
spectrum from each ROI and the average peak list were obtained. Peak intensities 
were compared by t-test. In order to check the homogeneity of the spectra set we 
carried out principal components analysis (PCA) with the Matlab algorithm and used 
the 3 primary PCAs for the 3-D scaling representation. To select the most relevant m/z 
peaks from the average peak list we used the loading plot coupled to each PCA 
graphic. We also obtained the area under the curve (AUC) of each m/z peak to assess 
the discrimination between contralateral (CL) and infarct (IC) of each m/z peak. 
Bottom-up protein identification strategies 
We set up two parallel strategies in order to maximize the number of identified 
proteins with molecular masses matching our relevant m/z obtained from MALDI IMS 
analysis. A diagram of the followed experimental workflow is shown in figure 1. 
Laser micro-dissection and protein extracts  
We mounted consecutive brain cryosections of 12 µm thickness obtained from the 
same 4 brains analyzed by the MALDI-IMS. Brain sections were alternatively put on 
PEN-membrane slides (Leica, Germany) and superfrost glass slides (Thermo Scientific), 
and were finally stored at -80 oC. Samples mounted on glass slides were used for IC 
localization through H&E staining and the same coordinates were used for laser 
microdissection. From the tissue sections mounted on PEN-membrane slides we 
dissected the IC and the CL areas (LMD6000 microscope, Leica) and recovered them 
separately into 25 µL of 0.1% Rapigest SF surfactant (Waters, USA). Samples were 














samples were centrifuged at 13,000g at 4ºC, the supernatants were recovered, 
supplemented with 4.5 µL of aprotinin (Sigma) and 10 µL of phenylmethylsulfonyl 
fluoride (Sigma) as protease inhibitors, and finally stored at -80oC until use. The 
obtained homogenates were fractionated on a 10-20% Tris-tricine gel (Biorad, USA) 
under reducing condition and stained with colloidal coomasie G250 (Bio-Rad). Four 
sections of each sample, IC and CL area, were cut from the gel. The gel bands, 
corresponding to the proteins with an apparent molecular weight bellow 25 kDa, were 
digested in-gel with trypsin and subsequently analyzed by MS/MS.  
Tissue homogenates and reverse phase HPLC (RP-HPLC) 
For RP-HPLC separations, mechanical homogenates of IC and CL areas of mouse brain 
were obtained in 0.2% of TFA and 60% of acetonitrile (ACN). Samples were sonicated 
using the parameters described above. Insoluble material was removed by 
centrifugation at 13,000 g at 4ºC, protease inhibitors were added into the recovered 
supernatant and samples were stored at -80oC until use. Soluble proteins were 
separated using the Alliance HPLC system (Waters) and a C4 widepore 3.6 µm; 4.6x100 
mm Aeris reverse phase (RP) column (Phenomenex). Solvent A was 0.1% TFA in water 
and solvent B was 0.1% TFA in ACN. A linear gradient from 10 to 30% for 1 min, 
followed by a second step from 30 to 90% for 60 min was applied. Fractions were 
collected every 2 min, dried using a SpeedVac (Thermo Scientific) and reconstituted in 
30 µL of H2O 0.1 % TFA mixed at 1:1 volume ratio with sinapinic acid matrix (10 g/ml, in 
1:2 H2O:ACN, 0.2 % TFA). Finally samples were mounted onto a ground steel plate, let 
to crystalize and mass spectra were obtained by MALDI MS analysis (lineal mode, 
24kV) to check for the presence of m/z of interest.   
Bottom-up nano LC-MS/MS 
Tryptic peptides from tricine gel sections and from RP-HPLC fractions of interest were 
analyzed on a LTQ Velos-Orbitrap mass spectrometer (ThermoFisher Scientific, 
Bremen, Germany) coupled to a nano-HPLC system (Proxeon Biosystems, Thermo 
Fisher Scientific, Bremen)). Briefly, peptide mixtures were initially concentrated on an 
EASY-column, 2 cm long, 100 μm internal diameter (id), and packed with ReproSil C18, 














chromatographed on an EASY-column, 75 μm id, 10 cm long, and packed with 
ReproSil-Pur C18-AQ, 3 μm particle size (Proxeon, Thermo Fisher Scientific). An ACN 
gradient (5− 35% ACN/0.1% formic acid in water, in 45 min, flow rate of 300 nL/min) 
was used to elute the peptides through a stainless steel nanobore emitter (Proxeon, 
Thermo Fisher Scientific) onto the nanospray ionization source of the LTQ Velos-
Orbitrap mass spectrometer. MS/MS fragmentation spectra (200 ms, 100− 2800 m/z) 
of 20 of the most intense ions, as detected from a 500 ms MS survey scan (300−1500 
m/z), were acquired using a dynamic exclusion time of 20 s for precursor selection and 
excluding single-charged ions. Precursor scans were acquired in the Orbitrap analyzer 
at a mass resolution of 30,000. MS/MS spectra were acquired at the LTQ Velos 
analyzer using normalized collision energy of 35%. An intensity threshold of 1,000 
counts was set for precursor selection. Orbitrap measurements were performed 
enabling the lock mass option (m/z 445.120024) for survey scans to improve mass 
accuracy. 
The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium[45] via the PRIDE partner repository with the dataset 
identifier PXD003644 and 10.6019/PXD003644. 
Bioinformatics for protein identification 
LC-MS/MS data were analyzed using the Proteome Discoverer software (Thermo Fisher 
Scientific) to generate mgf files. Processed runs were loaded to ProteinScape software 
(Bruker Daltonics, Bremen, Germany) and peptides were identified using Mascot 
(Matrix Science, London UK) to search the SwissProt 20160108 database, restricting 
taxonomy to mus musculus (16754 sequences).  MS/MS spectra were searched with a 
precursor mass tolerance of 10 ppm, fragment tolerance of 0.05 Da, trypsin specificity 
with a maximum of 2 missed cleavages, cysteine carbamidomethylation set as fixed 
modification and methionine oxidation as variable modification.  Significance threshold 
for the identifications was set to minimum ions score of 20, and the identification 















In order to match the relevant identified m/z peaks after MALDI IMS with the 
molecular masses of the proteins identified by bottom-up analysis, we used the 
PeptideMass tool from ExPasy (http://web.expasy.org/peptide_mass/)[46]. This tool 
allows the generation of the theoretical peptide masses of the input proteins. By 
selecting the “no cutting” parameter, all the putative fragments resulting after the 
post-translational processing of each protein were displayed (i.e. pro-form, signal 
sequences, transit peptides, active peptide, etc). All known post-translational 
modifications (PTMs) and variants of the proteins were considered and all other 
parameters were used as default. The identified MALDI-IMS m/z peaks were matched 
with the masses of proteins and/or peptides retrieved by PeptideMass considering a 
maximum mass shift of 2,000 ppm, which corresponds to the maximum peak shift 
allowed in peak alignment during the recalibration of MALDI IMS spectra. 
Verification of candidates 
Immunohystochemistry 
Some of the predicted proteins were selected based on their biological function and 
the availability of commercial antibodies to be confirmed by immunohistochemistry. 
Sections of 12 µm of thickness (+0.5 to +1.9 µm from bregma) were obtained from 
mouse brains previously fixed with PFA. The brains were cryoprotected with 30% 
sucrose in PBS, embedded in OCT and kept at -80 oC until use (N=4-5). Brain sections 
were acetone-fixed and subjected to antigen retrieval in citric acid (pH=6 / 95oC). 
Endogenous peroxidases were inactivated using 2% H2O2 and tissue was blocked with 
goat serum (5% in PBS- 0.1% tween) for 1 hour. Finally tissue sections were incubated 
overnight at 4oC with the corresponding primary anti-mouse antibody produced in 
rabbit against ATP5i (1/50) (Proteintech, USA), UMP-CMP Kinase (1/50) (Proteintech), 
COX6C (1/100) (Biorbyt, UK), FXYD7 (1/100) (Biorbyt), PLM (1/100) (Biorbyt), Nedd8 
(1/80)(Enzolifesciences, USA), ubiquitin (1/250) (Novus, USA), NEUG (1/500) 
(Proteintech), PDCD5 (1/25) (Proteintech). Biotinilated IgG anti-rabbit was applied as 
secondary antibody (Vector Laboratories, Burlingame, USA). Detection was performed 
using DAB systems (Dako, Denmark) followed by hematoxylin (Sigma) counterstaining. 














antibody. For immunohistochemistry quantification images were acquired (200x) from 
the IC region and from the CL equivalent section (2 images per region corresponding to 
the primary somatosensory area layer 2/3 and layer 5). Images from the respective 
negative control were used to set the threshold to consider positive staining when 
primary antibodies were present. Positive area was quantified using standard 
computer assisted technique based on ImageJ FIJI software. The IC positive-stained 
areas were normalized considering the corresponding CL quantified areas. Statistical 
comparisons were performed using T-test (SPSS 15.0 software). Mean and standard 
error are represented and a p-value less than 0.05 was considered significant for all 
comparisons. 
Western blot 
Mouse brain homogenates (n=3) of CL and IC areas were obtained and resolved on 10-
20% Tris-tricine gel under reducing conditions and transferred onto 0.45m 
polyvinylidene difluoride membranes (Millipore Corp). Membranes were blocked for 1 
hour with 10% nonfat milk (PBS 0.1% Tween 20) and later probed with anti-ATP5i 
(1/1000), anti- COX6C (1/800), anti- UMP-CMP Kinase (1/1000) and anti-β actin 
(1/20000) overnight at 4oC. Secondary antibodies (Chemicon International) anti-rabbit-
horseradish peroxidase (1:1000) from donkey or anti-mouse-horseradish peroxidase 
(1:1000) from sheep, were used for 1h incubations at room temperature with gentle 
agitation. Three washes with PBS-Tween were performed before and after the 
incubation with secondary antibodies. The substrate reaction was developed with 
chemiluminescent reagent Luminol (Amersham Biosciences, UK) and analyzed with 
LAS-3000 luminescent analyzer (Fujifilm, USA). Scanned Western blots were quantified 
using Image-J free software. Positive signal was corrected by actin used as loading 
control. IC-positive bands were normalized by the CL quantified bands and statistical 
comparisons were performed using T-test (SPSS 15.0 software). Mean and standard 

















We obtained the average spectra of the infarct (IC) and the contralateral (CL) healthy 
areas, and identified a total of 102 m/z values with different intensities between both 
regions (p<0.0001) (Figure 2A). PCA analysis revealed a good discrimination between IC 
and CL when PC1 was combined with PC2 and PC3 (Figure 2B). Using loading plot 
analysis we selected the 21 most-relevant m/z values (Figure 2B and 2C) and 
subsequently obtained their ion distribution map to visualize their positioning along 
the whole brain sections. All the m/z peaks colocalized with the injured infarcted area 
revealing an increase or a decrease in its relative abundance (table 1).  
Four out of the 21 most relevant m/z peaks showed a very high discrimination capacity 
between IC and CL with AUC>0.9 (figure 3). When other parts of the brain sections 
were visualized, the peak m/z 6726 was found more abundant in the ventral striatum 
whereas the peaks m/z 7545 and m/z 4815 were found increased in the cerebral 
cortex and the region of the pallidum respectively. In contrast, m/z 8458 appeared 
significantly increased in the IC area when compared with the equivalent region in the 
CL area and only the anterior commissure retrieved an elevated abundance compared 
to other parts of the healthy tissue. (Figure 3).  
Protein identification by Bottom-up approach 
We obtained the protein extract of the IC and CL areas from adjacent brain sections by 
means of laser microdissection and fractionated them through 1D tricine gels. Given 
that the proteins that were found most relevant in terms of discrimination capacity 
after MALDI-IMS analysis ranged from 4,285 to 22,178 m/z, the regions of the tricine  
gels comprised between 4 and 23 KDa were cut and digested with trypsin. After 
nanoLC-MS/MS analysis we identified a total of 666 proteins with at least 2 unique 
peptides: 257 were only found in CL, 61 in IC and 348 proteins were identified in 
homogenates from both regions, CL and IC (Supplemental table S1). After determining 
the masses of the identified proteins considering all the described PTMs, we matched 
8 m/z peaks with the MALDI-IMS results (Table 2).  
In a parallel approach we fractionated IC and CL brain homogenates by RP-HPLC using 
a C4 column and analyzed the obtained fractions by MALDI MS. The chromatographic 














values similar to some of the relevant m/z detected by MALDI-IMS (5708.072, 
8110.952, 8108.42, 8569.93, 8567.025, 6721.464, 7533.73, 22176.646)(Figure 4). 
These fractions were digested using trypsin and then analyzed through nanoLC-
MS/MS. As a result a total of 495 proteins were identified with ≥2 unique peptides 
(Supplemental table S2). Among the identified proteins we found matches for the m/z 
5708.072, 8110.95, 8569.93 and 8569.9, all of them previously reported in the MALDI-
IMS experiment. The proteins corresponding to these m/z were ATP5e, ATP5i, Nedd8 
and ubiquitin, which were identified with a sequence coverage>35% and an 
identification SCORE>60 (Table 3).  
Immunohistochemistry 
After the immunohistochemistry analysis, the proteins ATP5i and COX6C showed a 
higher expression in the IC region compared to the CL area (p<0.05 and p<0.2, 
respectively). In contrast, UMP-CMP kinase showed a significant decrease (p<0.01), 
confirming the results obtained by MALDI-IMS (Figure 5A, 5B and 5C).  
Western Blot 
As expected, western blot analyses in IC and CL regions from brain homogenates 
showed that, ATP5i expression was increased in IC whereas UMP-CMPK was 
decreased. In contrast, no differences were found in COX6C expression when both 
regions were compared. 
Discussion 
The present study shows for the first time the profiling and spatial distribution of 
proteins along different regions of mouse brain subjected to focal ischemia using the 
state of the art technique MALDI IMS. 
During the last decade, the identification of the protein identity related to each m/z 
peak has generally been elusive in studies applying MALDI-IMS, precluding the 
validation of the results and the elucidation of the biological processes involved. 
However, different identification approaches have been developed by MALDI imaging 














imaging data represent an effective approach for protein identity verification [47]. An 
alternative strategy that has been proven successful consist of the comparison of the 
presence and distribution of the protein of interest between wild type animals and 
knockout experimental models [48,49]. Recently, important steps forward were made 
with the optimization of on-tissue digestion protocols [50]. Following tryptic digestion, 
protein identification can be reached after the analysis of the generated peptides. 
However, low fragmentation efficiencies and high background signal are important 
challenges to overcome. A significant advancement was achieved in molecular imaging 
strategies with the use of MALDI FITCR IMS for the analysis of tissue sections [51,52]. 
MALDI FITCR IMS provides the highest mass resolution and accuracy and allows the 
obtaining of high spatial resolution images. These improvements might facilitate a 
substantial progress to effectively link proteomic experiments with imaging data in 
future studies thanks to the application of next generation analytical tools.  
In our study, after MALDI IMS analysis, we followed a bottom-up strategy to correlate 
imaging with proteomic analyses. As a result we identified a total of 21 relevant 
protein species differently expressed in IC compared to the CL region. We were able to 
identify different proteins after the development and combination of different sample 
fractionation methods based on size or hydrophobicity separation. In addition, after 
the bottom-up analysis we took into account the putative post-translationally modified 
forms of the identified proteins to become one step closer to the real tissue 
phenotype, where PTMs and protein processing occur. Following this strategy we 
identified and confirmed ATP5i, COX6C and UMP-CMP kinase as proteins related to 
brain ischemia. 
During cerebral ischemia the production of cellular energy is impaired and ATP 
concentration decreases promoting the depolarization of the neuron membranes and 
causing an imbalance of Na+, K+ and Ca2+ [53]. This alteration of the ion homeostasis 
induces the release of neurotransmitters, further inhibits the production of ATP and 
activates endogenous proteases enlarging the cytotoxic response to ischemia. Ischemic 
injury also increases the amounts of reactive oxygen species (ROS) which attack key 
cellular components, especially in the reperfused regions [54]. We identified two 














with the healthy contralateral area of the brain. Both proteins are members of the 
oxidative phosphorylation pathway (OXPHOS) thus involved in the production of 
energy in eukaryotic cells resulting from the oxidation of nutrients. ATP5i is the subunit 
e of the F0 complex, which comprises the proton channel in the ATP synthase complex 
in the inner membrane of the mitochondria [55]. Our results are in line with others’ in 
which ATP synthase complex 5 together with other mitochondrial proteins has been 
found increased in the middle cerebral arteries isolated from the ischemic region 
compared with the healthy area and non-ischemic animals [56]. After MALDI IMS 
analysis we also found the m/z 5712 increased in IC. This m/z value might correspond 
to the ATP synthase complex subunit ATP5E although these results could not be 
replicated by immunohistochemistry. In contrast, ATP5 subunit beta has been found 
significantly decreased in rat cortical neurons after chemically induced ischemia [57]. 
These divergences might reflect the different response to ischemia of the components 
of the neurovascular unit. Similarly to ATP5i, we found an increased abundance of the 
Cytochrome c oxigenase (COX) complex subunit COX6C in the IC of the brain compared 
to the CL area. COX6C is a nuclear-coded polypeptide that is tightly bound to the 
catalytic subunits I and II [58] and its expression together with other COX subunits has 
been found altered in neurological diseases such as Alzheimer’s [59]. Although no 
specific function has been yet described for COX6C it may be involved in the regulation 
and assembly of the complex COX. COX is the last heteromeric complex (complex IV) of 
the mitochondrial respiratory chain that catalyzes the electron transfer to oxygen. Its 
inhibition due to the lack of oxygen is a central initial process of the ischemic damage 
[60]. The increase of ATP5i and COX6C expression found through our analysis by 
MALDI-IMS might be promoted by the requirement of a greater mitochondrial function 
to restore oxidative phosphorylation after ischemia. This compensatory effect against 
the lack of oxygen might be promoted by the increase of total mitochondrial mass 
after ischemia due to mitochondrial biogenesis [61,62]. Interestingly, COX activity has 
been found altered after ischemic stroke in cerebrospinal fluid and erythrocyte 
hemolysate of patients compared to healthy controls [63]. In other analyses performed 
in brain tissue, some authors have found increased expression of COX subunit I after 
global cerebral ischemia [64]. In contrast, others have found a COX subunit I decrease 














These controversies may reflect the dependence of the process on the time of 
ischemia and reperfusion [66]. Deficiencies in COX function, expression or assembly 
have been related with other diseases such as the mitochondrial disorders Leigh 
Syndrome [67], neonatal hypertrophic cardiomyopathy [68] or early-onset 
leukodystrophic encephalopathy [69].  
The modulation of proteins members of the OXPHOS pathway has been already 
considered for neuroprotection [70,71]. Although the strategies of ROS scavenging 
have resulted futile, the uncoupling of mitochondrial membrane potential through the 
stimulation of proton channels and the induction of OXPHOS complexes 
phosphorylation seem promising approaches that may reduce the effects of ischemia 
[66]. Our results suggest the implication of the subunits ATP5i and COX6C in the brain 
infarct development, thus presenting them as potential molecules to modulate and 
minimize neuronal injury.  
On the other hand, UMP-CMP kinase acts as an uridylate-cytidylate kinase that 
catalyzes the phosphorylation of CMP and UMP with the consequent formation of the 
nucleosides CDP and UDP, which are further phosphorylated to its triphosphate forms 
at the expense of ATP [72]. These nucleosides are required for the cellular nucleic acid 
synthesis [73] but they also play important roles in neuronal function. More precisely, 
they are involved in the regulation of adenylate cyclase and protein synthesis, as well 
as sugar metabolism, synthesis of phospholipids and release of neurotransmitter [74]. 
During brain ischemia, a decrease in the levels of CTP and UTP has been observed [75], 
and the exogenous administration of these nucleosides has been proven to be 
neuroprotective in different models of brain ischemia [74]. A decreased expression of 
UMP-CMP kinase in the mouse cerebral cortex has been related to aging [76] but, to 
our knowledge, no study has explored UMP-CMP kinase in brain ischemia. In this 
regard we found a decreased expression of UMP-CMP kinase in the IC compared to the 
CL healthy area of mouse brain. This finding suggests that UMP-CMP kinase might play 
a role in the modulation and promotion of the pyrimidine nucleoside metabolism 















The application of MALDI-imaging allowed us to compare the relative abundance of 
proteins at different regions of interest and to identify new potential biomarkers of 
brain ischemia or candidate therapeutic targets for tissue recovery. After the 
combination of two different identification strategies after bottom-up analysis, four 
proteins were identified in both approaches.  
Our study stands with some limitations. Despite different attempts, we were not able 
to obtain good quality spectra after on-tissue trypsin digestion (data not shown). The 
results of this analysis might have permitted the identification of further putative 
candidates. By the development of the strategies presented in our study we were able 
to identify different protein candidates, however, apart from COX6C (m/z 8458), we 
failed to identify other m/z that retrieved a very high discrimination ability between IC 
and CL (with AUC>0.9). In addition, we were not able to obtain chromatographic 
fractions highly enriched with proteins of interest in order to perform a top-down 
approach for protein identification (not shown). The protein identification based on 
bottom-up analysis is limited by i) the mass error inherent to MALDI-imaging  in the 
analysis of intact proteins, and ii) the presence of PTMs which can difficult the protein 
mass calculation based on the aminoacid sequence. The mass tolerance considered to 
link the MALDI IMS data with bottom-up results was 2,000 ppm, a narrow tolerance 
window similar to other authors’ [36,77,78]. During this process, all PTMs that are 
described for each protein were taken into account although protein-m/z matching 
based on molecular weight is complex especially in the analysis of big biomolecules. 
Thus, the presence of false negative and false positive identifications cannot be 
excluded. In spite of that, we validated some of the candidates by orthogonal 
methodologies and found patterns of expression which are coherent with MALDI 
imaging data. Our identification strategy might be improved in near future considering 
unspecific protein degradation by endogenous proteases. 
Future additional studies are needed to confirm our findings. The application of MALDI 
IMS in other models of brain ischemia and with different times of occlusion might also 
help in finding proteins involved in the early response to brain ischemia. Future studies 















We characterized for the first time the protein profile and distribution of brain 
subjected to ischemia and we were able to determine changes in protein abundance in 
a murine model using MALDI imaging MS. Proteomic results were confirmed by 
immunohistochemistry and western blot in independent samples and the identified 
candidates might represent putative candidates to become biomarkers or molecular 
targets in brain ischemia. 
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Figure 1: Diagram of the experimental workflow followed for the analysis of mouse 
brain after ischemia by MALDI-IMS. Two parallel strategies with different sample 
fractionation approaches were performed. In a first approach, protein extracts from 
infarct core (IC) and healthy contralateral area (CL) were obtained by means of laser 
micro-dissection and were separated using a tricine gel. In a second approach, tissue 
homogenates from both IC and CL were fractionated by RP-HPLC and fractions were 
analyzed by MALDI MS. Both, the bands excised from tricine gels, and the fractions of 
interest obtained from RP-HPLC, were trypsin digested and analyzed using an Orbitrap 
LTQ velos mass spectrometer.  
Figure 2: A) Average spectra obtained from the regions of interest (ROIs) considered 
for the comparative analysis. ROI 1 corresponds to the infarct core (IC) on the cortical 
region, whereas ROI 2 was set on the corresponding healthy contralateral (CL) area of 
the brain (n=4). B) Principal Components Analysis (PCA) of the obtained spectra 
showed the discrimination of both ROIs based on the obtained mass spectra. Each dot 
from the dot plot represent a mass spectra obtained from IC (red) and CL (green). C) 
The 102 m/z  peaks that showed significant differences between IC and CL are 
distributed in loading plots. Some of the 21 most relevant m/z peaks appear 
highlighted. I: m/z  8458; II: m/z 8573; III: m/z 6855; IV: m/z 4815; V: m/z 6726; VI: 
m/z 5449; VII: m/z 7545; VIII: m/z 6655; IX: m/z 4969; X: m/z 14999; XI: m/z 15630. 
Scale bar, 500µm. 
Figure 3: Ion density maps corresponding to m/z 6726, m/z 7545, m/z 4815 and m/z 
8458. Peaks 6726, 7545 and 4815 show a reduced intensity in the infarct region when 
compared with the healthy contralateral area. Red-white pixels represent a high 
abundance whereas blue-dark pixels correspond to regions with low abundance or 
absence of the corresponding m/z. The image on the right represents the 
hematoxylin&eosin staining of the corresponding brain section after being analyzed by 















Figure 4: Mass spectra obtained after the analysis by MALDI MS of the fractions 
obtained by reverse phase HPLC. The corresponding retention times were 24 (A), 26 
(B) and 28 (C) min, respectively. The arrows indicate those m/z that had been 
identified by MALDI-IMS as putative discriminatory peaks. These fractions were 
digested with trypsin and analyzed through nanoLC MS/MS. The identified proteins 
were matched with the corresponding MALDI MS m/z, taking into account their 
molecular weight (m. w.) including post-translational modifications. The m/z 8108.426 
matched with ATP5i (m. w. of 8100.43, after loss of initial methionine); the m/z 
8569.934 and m/z 8567.025 matched with ubiquitin (m. w 8560.62 Da) and Nedd8 (m. 
w. 8555.67 Da, after loss of C-terminal fragment); and the m/z 5708.072 matched with 
ATP5E (m. w. of 704.12 Da, after loss of initial methionine). 
Figure 5: Identification of ATP5i (corresponding to m/z 8112)(A), COX6C (m/z=8458)(B) 
and UMP-CMP kinase (m/z=22178)(C) were confirmed by IHC. The percentage of 
positive signal was determined in 2 fields from each region of interest and averaged.  
The percentage of positive signal is represented as normalized signal considering CL as 
reference. (D) Western blot analysis of ATP5i, COX6C and UMP-CMP kinase in mouse 
brain homogenates. 
*p<0.05,  ** p<0.01; # p<0.2 
Scale bar in immunohistochemistry images: 50 µm (200X) 
Scale bar in MALDI imaging and H&E staining: 500µm 
ATP5i: ATP synthase subunit e; COX6C: cytochrome oxidase subunit VI C; CL: 














Table 1: Most relevant 21 m/z peaks identified after MALDI-IMS analysis.  
m/z peak CL vs IC  
CL average 




4286 CL<IC 3.75±0.27 5.68±0.55 
4752 CL>IC 6.73±0.60 3.59±0.79 
4815 CL>IC 14.03±1.96 3.54±0.56 
4942 CL>IC 11.09±2.60 6.39±0.77 
4969 CL>IC 48.01±3.74 16.95±2.44 
5175 CL>IC 6.04±0.43 4.18±0.60 
5712 CL<IC 5.16±0.54 7.17±0.86 
6282 CL>IC 7.78±2.03 4.04±0.66 
6655 CL>IC 9.81±3.19 4.33±0.47 
6726 CL>IC 37.99±10.84 8.43±2.13 
7074 CL>IC 8.26±1.02 4.67±0.63 
7545 CL>IC 24.41±7.75 4.62±0.35 
8112 CL<IC 3.69±0.25 4.38±0.60 
8458 CL<IC 2.86±0.14 6.27±0.63 
8499 CL<IC 3.30±0.16 4.51±0.36 
8573 CL<IC 15.48±3.08 24.33±3.10 
8738 CL<IC 2.50±0.23 4.06±0.57 
9088 L>IC 5.58±0.22 3.24±0.60 
14145 CL>IC 13.28±2.83 3.73±1.02 
14999 CL<IC 1.08±0.08 1.77±0.62 
22178 CL>IC 1.76±0.30 1.14±0.25 
 
All m/z showed a p-value <0.000001 
















Table 2: Matching between the m/z peaks from MALDI-IMS and the proteins identified after SDS-tricine gels followed by nanoLC-MS/MS analysis. 
 






Protein name Id SCORE (CL, IC) SC% (CL, IC) Predicted PTM MW (Da) 
6282 USMG5_MOUSE Up-regulated during skeletal muscle growth protein 5 80.4, 47  44.8, 17.2 




RAB1B_MOUSE Ras-related protein Rab-1B 281.3, 36.5 34.3, 7.5 - 22174.23 
KCY_MOUSE UMP-CMP kinase 35.6, 55.2 11.2, 12.8 1 acetylation 22194.34 
14145 
PDCD5_MOUSE Programmed cell death protein 5 129, -- 30.2, - loss of initial methionine 14136.31 
NDUC2_MOUSE NADH dehydrogenase [ubiquinone] 1 subunit C2 71.2, 41.8 10.8, 16.7 - 14155.24 
8458 COX6C_MOUSE Cytochrome c oxidase subunit 6C 356.3, 184.5 72.4, 56.6  - 8464.51 
5712 ATP5E_MOUSE ATP synthase subunit epsilon, mitochondrial 93.9, 73.2  53.8, 73.1 loss of initial methionine 5704.12 
8499 
FXYD7_MOUSE FXYD domain-containing ion transport regulator 7 99.7, 70.4  20, 20 - 8482.25 
PLM_MOUSE Phospholemman 57.3, 50.6  21.7, 21.7 
loss of signal peptide and 2 
phosphorylations 
8508.34 
7545 NEUG_MOUSE Neurogranin 144.3, 102.6 26.9, 26.9 1 acetylation 7534 
8573 
NEDD8_MOUSE NEDD8 89.1, - 38.3, - loss of c-terminal 8555.67 
RS27A_MOUSE Ubiquitin-40S ribosomal protein S27a 938.1, 486.5 32.7, 25 Chain Ubiquitin at positions 1 - 76 8560.62 














Table 3: Correspondence between the m/z peaks from MALDI-IMS and the proteins identified after RP-HPLC fractionation of brain homogenates and 
nanoLC-MS/MS analysis. 





Protein name Id SCORE SC% Predicted PTM MW (Da) Fraction RT (min) 
8112 8110.95 ATP5I_MOUSE ATP synthase subunit e, mitochondrial 6199 71.8 loss of initial methionine 8100.43 24, 26 
8573 8569.93 RS27A_MOUSE Ubiquitin-40S ribosomal protein S27a 1507.3 28.2 Ubiquitin fragment 8560.62 24, 26, 28 
8573 8569.93 NEDD8_MOUSE NEDD8 221.6 51.9 
loss of c-terminal fragment 8555.67 24, 26 





ATP synthase subunit epsilon 64.8 44.2 loss of initial methionine 5704.12 24, 26 
 
Id SCORE: score of identification; SC%: percentage of sequence coverage; PTM: post-translational modifications; MW: molecular weight considering the 
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Significance: We identified for the first time using MALDI-IMS new proteins that might 
be involved in brain ischemia representing potential diagnostic biomarkers or target 

















- We performed a protein profile analysis of brain tissue subjected 
to ischemia.  
- We identified protein species (m/z values) involved in brain 
ischemia using two different identification approaches.  
- A novel strategy was carried out to match m/z with protein 
molecular weights. 
- Identified proteins represent potential biomarkers/therapeutic 
targets for neurological recovery after cerebral ischemia. 
